📊 ARDX Key Takeaways
Is Ardelyx, Inc.. (ARDX) a Good Investment?
Ardelyx exhibits severe operational challenges with massive losses despite 22% revenue growth, indicating poor unit economics and inability to monetize sales effectively. The company faces critical cash burn (-$44M FCF) with only 68M cash reserves against 202.8M long-term debt, creating near-term solvency concerns unless losses narrow significantly.
Ardelyx is delivering solid top-line growth, but the quality of that growth is weak because revenue expansion is not translating into durable profitability or cash generation. Margins remain deeply challenged, free cash flow is negative, and leverage is meaningful relative to equity, leaving the company dependent on continued execution improvement to strengthen its financial profile.
Why Buy Ardelyx, Inc.. Stock? ARDX Key Strengths
- Strong revenue growth of 22.1% year-over-year demonstrates market demand for products
- Solid liquidity position with 4.31x current ratio provides near-term operational flexibility
- Positive insider activity with 20 Form 4 filings in last 90 days suggests management confidence
- Revenue growth remains strong at 22.1% YoY, indicating continued commercial traction
- Liquidity is solid with a 4.31x current ratio and $68.0M in cash, supporting near-term operations
- Asset base exceeds liabilities, with positive stockholders' equity of $166.95M
ARDX Stock Risks: Ardelyx, Inc.. Investment Risks
- Catastrophic profitability with -15.1% net margin and operating losses of $41M despite $407M revenue indicates fundamental business model problems
- Negative free cash flow of $44M annually is unsustainable; at current burn rate, cash reserves could deplete within 1-2 years without additional financing
- Excessive leverage with 1.21x debt-to-equity ratio and $202.8M long-term debt against $68M cash creates significant refinancing risk
- Deteriorating EPS trend (-52.9% YoY) despite revenue growth signals worsening operational performance
- Negative interest coverage of -17.4x indicates company cannot service debt from operations
- Profitability remains weak, with negative operating income, negative net income, and just a 1.1% gross margin
- Cash generation is poor, with negative operating cash flow and negative free cash flow
- Balance sheet leverage is elevated, with debt/equity at 1.21x and negative interest coverage signaling debt-servicing strain
Key Metrics to Watch
- Operating cash flow trend - critical to determine if losses are stabilizing or accelerating
- Gross margin expansion - 1.1% is abnormally low and must improve for viability
- Debt refinancing schedule and covenant compliance - essential given high leverage and negative EBITDA
- Path to profitability timeline - company must demonstrate realistic turnaround plan
- Operating margin and gross margin improvement
- Operating cash flow and free cash flow trend
Ardelyx, Inc.. (ARDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.31x current ratio provides a solid financial cushion.
ARDX Profit Margin, ROE & Profitability Analysis
ARDX vs Healthcare Sector: How Ardelyx, Inc.. Compares
How Ardelyx, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ardelyx, Inc.. Stock Overvalued? ARDX Valuation Analysis 2026
Based on fundamental analysis, Ardelyx, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ardelyx, Inc.. Balance Sheet: ARDX Debt, Cash & Liquidity
ARDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ardelyx, Inc..'s revenue has grown significantly by 3,934% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
ARDX Revenue Growth, EPS Growth & YoY Performance
ARDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $98.2M | -$809.0K | $0.00 |
| Q2 2025 | $73.2M | -$16.5M | $-0.07 |
| Q1 2025 | $46.0M | -$26.5M | $-0.11 |
| Q3 2024 | $56.4M | -$809.0K | $0.00 |
| Q2 2024 | $22.3M | -$16.5M | $-0.07 |
| Q1 2024 | $11.4M | -$26.5M | $-0.11 |
| Q3 2023 | $5.0M | $6.6M | $0.03 |
| Q2 2023 | $2.5M | -$17.1M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ardelyx, Inc.. Dividends, Buybacks & Capital Allocation
ARDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ardelyx, Inc.. (CIK: 0001437402)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARDX
What is the AI rating for ARDX?
Ardelyx, Inc.. (ARDX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARDX's key strengths?
Claude: Strong revenue growth of 22.1% year-over-year demonstrates market demand for products. Solid liquidity position with 4.31x current ratio provides near-term operational flexibility. ChatGPT: Revenue growth remains strong at 22.1% YoY, indicating continued commercial traction. Liquidity is solid with a 4.31x current ratio and $68.0M in cash, supporting near-term operations.
What are the risks of investing in ARDX?
Claude: Catastrophic profitability with -15.1% net margin and operating losses of $41M despite $407M revenue indicates fundamental business model problems. Negative free cash flow of $44M annually is unsustainable; at current burn rate, cash reserves could deplete within 1-2 years without additional financing. ChatGPT: Profitability remains weak, with negative operating income, negative net income, and just a 1.1% gross margin. Cash generation is poor, with negative operating cash flow and negative free cash flow.
What is ARDX's revenue and growth?
Ardelyx, Inc.. reported revenue of $407.3M.
Does ARDX pay dividends?
Ardelyx, Inc.. does not currently pay dividends.
Where can I find ARDX SEC filings?
Official SEC filings for Ardelyx, Inc.. (CIK: 0001437402) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARDX's EPS?
Ardelyx, Inc.. has a diluted EPS of $-0.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ARDX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ardelyx, Inc.. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ARDX stock overvalued or undervalued?
Valuation metrics for ARDX: ROE of -36.9% (sector avg: 15%), net margin of -15.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ARDX stock in 2026?
Our dual AI analysis gives Ardelyx, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARDX's free cash flow?
Ardelyx, Inc..'s operating cash flow is $-42.5M, with capital expenditures of $1.5M. FCF margin is -10.8%.
How does ARDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -15.1% (avg: 12%), ROE -36.9% (avg: 15%), current ratio 4.31 (avg: 2).